相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death
Oriana Hoi Yun Yu et al.
CANADIAN JOURNAL OF DIABETES (2015)
Treating Diabetes Mellitus in Older and Oldest Old Patients
A. M. Abbatecola et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study
P. Valensi et al.
DIABETES & METABOLISM (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2015)
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension
S. -M. Jin et al.
DIABETES OBESITY & METABOLISM (2015)
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial
B. Gallwitz et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study
G. Leibowitz et al.
DIABETES OBESITY & METABOLISM (2015)
Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
A. S. Abdelmoneim et al.
DIABETES OBESITY & METABOLISM (2015)
Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
S. E. Inzucchi et al.
DIABETES OBESITY & METABOLISM (2015)
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-A retrospective nationwide study
Ulrik Madvig Mogensen et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
Wolfgang Kothny et al.
DIABETOLOGIA (2015)
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETOLOGIA (2015)
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial
Paul Hartley et al.
DRUGS & AGING (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
Nobuya Inagaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes
A. Avogaro et al.
DIABETES OBESITY & METABOLISM (2015)
Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
Jong-Mi Seong et al.
PLOS ONE (2015)
Dipeptidyl Peptidase-4 Greatly Contributes to the Hydrolysis of Vildagliptin in Human Liver
Mitsutoshi Asakura et al.
DRUG METABOLISM AND DISPOSITION (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Michael Lehrke et al.
CLINICAL THERAPEUTICS (2014)
Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and Isoglycemic Intravenous Glucose
Irfan Vardarli et al.
DIABETES (2014)
Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk
Elaine Chow et al.
DIABETES (2014)
Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias
Annett Stahn et al.
DIABETES CARE (2014)
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
Itamar Raz et al.
DIABETES CARE (2014)
Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study
C. Ll Morgan et al.
DIABETES OBESITY & METABOLISM (2014)
Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality
C. Ll Morgan et al.
DIABETES OBESITY & METABOLISM (2014)
A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
T. M. E. Davis
DIABETES OBESITY & METABOLISM (2014)
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
Boaz Hirshberg et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis
J. E. Schopman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Risk of pancreatitis in patients treated with incretin-based therapies
Juris J. Meier et al.
DIABETOLOGIA (2014)
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
Tesfaye Biftu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
Yoshinobu Nakamaru et al.
XENOBIOTICA (2014)
Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
Namtae Kim et al.
XENOBIOTICA (2014)
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Namyi Gu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
Bo Ahren et al.
DIABETES THERAPY (2014)
Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
Paul Craddy et al.
DIABETES THERAPY (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study
Carolina Solis-Herrera et al.
DIABETES CARE (2013)
Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
David M. Nathan et al.
DIABETES CARE (2013)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
E. J. Rhee et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
Giuseppe Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2013)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
O. J. Phung et al.
DIABETIC MEDICINE (2013)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS' COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 CONSENSUS STATEMENT - EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2013)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Carolyn F. Deacon et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry
A. K. Gitt et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Shinji Furuta et al.
XENOBIOTICA (2013)
Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
Daniel A. Tatosian et al.
DIABETES THERAPY (2013)
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Samuel S. Engel et al.
DIABETES THERAPY (2013)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Pharmacokinetics of linagliptin in subjects with hepatic impairment
Ulrike Graefe-Mody et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers
Yook-Hwan Noh et al.
CLINICAL THERAPEUTICS (2012)
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c value
Karl J. Krobot et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study
B. Guerci et al.
DIABETES & METABOLISM (2012)
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition
Maria Rosaria Rizzo et al.
DIABETES CARE (2012)
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
A. S. Abdelmoneim et al.
DIABETES OBESITY & METABOLISM (2012)
Treating diabetes today: a matter of selectivity of sulphonylureas
S. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
K. Goossen et al.
DIABETES OBESITY & METABOLISM (2012)
Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England
A. J. Farmer et al.
DIABETIC MEDICINE (2012)
Heterozygous ABCC8 mutations are a cause of MODY
P. Bowman et al.
DIABETOLOGIA (2012)
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas
Martin Javorsky et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
Noriyasu Kato et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
David W. Boulton et al.
CLINICAL PHARMACOKINETICS (2011)
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Daniel S. Budnitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
Anja Schweizer et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
C. Filozof et al.
DIABETIC MEDICINE (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
Raffaele Marfella et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
β-Cell-Mediated Signaling Predominates Over Direct α-Cell Signaling in the Regulation of Glucagon Secretion in Humans
Benjamin A. Cooperberg et al.
DIABETES CARE (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Bo Ahren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator
Jussi Aittoniemi et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2009)
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
B. F. Burkey et al.
DIABETES OBESITY & METABOLISM (2008)
Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury
Elizabeth Murphy et al.
PHYSIOLOGICAL REVIEWS (2008)
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Testing the bipartite model of the sulfonylurea receptor binding site:: Binding of A-, B-, and A+B-site ligands
Marcus Winkler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Variation in TCF7L2 influences therapeutic response to sulfonylureas -: A GoDARTs study
Ewan R. Pearson et al.
DIABETES (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Ewan R. Pearson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia
E Szoke et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
DJ Augeri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Oral antidiabetic agents - Current role in type 2 diabetes mellitus
AJ Krentz et al.
DRUGS (2005)
Therapeutic strategies based on glucagon-like peptide 1
CF Deacon
DIABETES (2004)
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
JJ Meier et al.
HEART (2004)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Impairment of myocardial protection in type 2 diabetic patients
TM Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
HB Rasmussen et al.
NATURE STRUCTURAL BIOLOGY (2003)
Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV
C Olsen et al.
GENE (2002)
Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide
A Holstein et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2001)
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8
CA Abbott et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1α gene mutations:: evidence for pharmacogenetics in diabetes
ER Pearson et al.
DIABETIC MEDICINE (2000)
分享论文
